IFNA2 and COVID-19: It is worth noting that the three autoAb-positive patients hospitalized with COVID-19 in 2020 (P18, P28, and P32; Fig. 2 D, Fig. S1 B, and Fig. S2 A) first developed neutralizing anti-IFNα2 autoAbs in 2008, 2013, and 2014 (i.e., 6–12 years prior to the start of the pandemic).